Navigation

Summary of Results

Health Topic:   Musculoskeletal
Guidance:   Osteoporosis - primary prevention
Description:   The summary of the published technology appraisal on Osteoporosis - primary prevention. It links to the published guidance and key documents.

NICE implementation uptake reports

Implementation uptake report Assessment Published Date Coverage

External literature

External literature Assessment Coverage

NHS Information Centre for Health and Social Care (2009) Use of NICE appraised medicines in the NHS in England-Experimental Statistics NHS Information Centre for Health and Social Care

Description: The NICE costing template expected an annual number of 586.1 thousand patients. Assuming that treatment is continuous this would lead to a predicted use of 213,917.0 thousand doses per annum. The observed use in 2008 was 256,691.7 thousand defined daily doses giving a ratio of 1.2 to 1.

Practice appears to be in line with guidance National

Turk A et al (2010) Pharmacist independent prescribing - An evaluation of care for patients admitted with fragility fractures Osteoporosis International 21 (Suppl 3):S443-S518

Description: Over a 21 month period all patients included in the study were examined by the Pharmacist Independent Prescriber (PIP) for treatments appropriate to secondary prevention of osteoporotic fragility fractures (FF). The PIP assessed 133 inpatients admitted following a fall; three had not suffered a FF but were assessed for primary prevention of osteoporosis as per NICE guidance. The remaining 130 patients had sustained a total of 149 FFs. 8% were referred for DXA scan following NICE guidance.

Doubts about or mixed impact in practice Local

Johnston, T et al (2010) Naughty or 'Nice': Has NICE TA160 changed our prescribing practice? Osteoporosis International 21 (suppl 3): S443-S518

Description: The authors compared prescribing against NICE 'eligibility' for primary prevention of osteoporosis in two groups of patients treated for this indication in the period April to 2007-Feb 2009 and subsequent to Feb 2009 toFeb 2010 NICE guidance. Results found that for risedronate/etidronate, 25.0% of prescribing in the pre-cohort conformed, increasing to 33.3% in the post-NICE cohort.

Doubts about or mixed impact in practice Local

The NHS Information Centre for Health and Social Care (2011) Use of NICE-appraised medicines in the NHS in England-2009, Experimental Statistics

Description: This is the second report commissioned by the Metrics Working Group to look at the variation in use of postively appraised medicines in relation to the expected use as predicted by NICE. In all, 47 medicines in 18 groups, relating to 29 technology appraisals were considered. Out of the 12 groups where a comparison could be made (these are presented in Section 1 of the technology section results), observed use by the NHS in England was higher than the predicted use for eight and lower for three.

Not graded National

Richards, M (2010) Extent and causes of international variation in drug usage: A report for the Secretary of State for Health by Professor Sir Mike Richards CBE

Description: This report looks at medicines usage between countries, using IMS Health data. The WHO defined daily dose or the maximum or prescribed daily dose was used to measure usage. Results rank the UK relative to other countries usage and present calculations showing how close or otherwise the UK is to the average use across groups of other countries. It should be noted that countries other than the UK would not be expected to adhere to NICE guidance making comparisons between countries not possible.

Not graded National

Royal College of Physicians (2012) Report of the 2011 inpatient falls pilot audit

Description: This pilot audit examined services for inpatients vulnerable to falls in acute and community hospitals and mental health units. Data was collated from 46 NHS trusts between 1 Nov and 13 Dec 2011. Despite ?pockets of excellent practice? the report found that falls assessments & interventions are not consistently provided for eligible patients - 23% had no review of  medication, 40% did not have their vision assessed, and 47% were not assessed for osteoporosis. 

Doubts about or mixed impact in practice National

Health and Social Care Information Centre (2012) Use of NICE-appraised medicines in the NHS in England - 2010 and 2011, Experimental Statistics

Description: This is the 3rd report published by the HSCIC on behalf of the DH to look at the variation in use of positively appraised medicines in relation to the expected use as predicted by NICE. In all, 52 medicines in 25 groups, relating to 35 technology appraisals were considered. Out of the 12 groups where a comparison could be made, observed use by the NHS in England was higher than the predicted use for 6 and lower for 6. For one drug group use was lower on one measure, and higher on another.

Not graded National

This page was last updated: 01 October 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.